US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Voya Infrastructure Industrials and Materials Fund

12.50

-0.2100-1.65%

Volume:23.08K

Turnover:288.30K

Market Cap:189.45M

PE:- -

High:12.69

Open:12.68

Low:12.34

Close:12.71

52wk High:14.30

52wk Low:11.36

Shares:15.16M

Float Shares:15.16M

Volume Ratio:1.18

T/O Rate:0.15%

Dividend:1.20

Dividend Rate:9.60%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Voya Equity Closed End Funds Declare Distributions

Power Grids Across Provinces Collaborate for Seamless Infrastructure Upgrade

Press Release: Voya Equity Closed End Funds Declare Distributions

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND, VOYA GLOBAL EQUITY DIVIDEND AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval

CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia

Press Release: Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update

Press Release: Voya Equity Closed End Funds Declare Distributions

Voya funds IGA, IDE declare May monthly distributions of $0.085, $0.1 per share

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Press Release: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

GlucoTrack Files IDE for Implantable Glucose Monitor

InspireMD announces FDA approval of IDE application for CGUARDIANS III study

enVVeno Medical Wins FDA IDE for TAVVE Trial

Adagio Medical reports six-month results from Fulcrum-VT IDE trial

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)

Programmable Logic Redefined for Simpler, Smarter, Fully Integrated Designs

Voya funds IGA, IDE declare April monthly distributions of $0.085 and $0.10 per share

Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/IDE/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IDE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","market":"US","secType":"STK","nameCN":"Voya Infrastructure Industrials and Materials Fund","latestPrice":12.5,"timestamp":1789403627071,"preClose":12.71,"halted":0,"volume":23084,"delay":0,"changeRate":-0.01652242328874908,"floatShares":15156320,"shares":15156320,"eps":0,"marketStatus":"Trading","change":-0.21,"latestTime":"09-14 12:42:55 EDT","open":12.68,"high":12.685,"low":12.3429,"amount":288302.678024,"amplitude":0.026916,"askPrice":12.51,"askSize":100,"bidPrice":12.39,"bidSize":60,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789416000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.71,"aum":0,"dividendRate":0.096016,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":12.71,"preClose":12.71,"latestTime":"19:30 EDT","volume":12,"amount":152.52,"timestamp":1789169406323,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.183685},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IDE\",,,,,undefined,":{"symbol":"IDE","floatShares":15156320,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.183685,"shares":15156320,"dividePrice":1.2002,"high":12.685,"amplitude":0.026916,"preClose":12.71,"low":12.3429,"week52Low":11.36,"pbRate":"--","week52High":14.3,"institutionHeld":0,"latestPrice":12.5,"committee":-0.25,"eps":0,"divideRate":0.096016,"volume":23084,"delay":0,"ttmEps":0,"open":12.68,"prevYearClose":12.3,"prevWeekClose":12.71,"prevMonthClose":13.13,"prevQuarterClose":13.84,"fiveDayClose":13.04,"twentyDayClose":13.35,"sixtyDayClose":13.75},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IDE\",params:#limit:5,,,undefined,":[{"date":"2026-09-01","symbol":"IDE","amount":0.1,"announcedDate":"2026-08-17","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-01","defaultRemindTime":1788269400000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-15","payableDate":"2026-09-01","currency":"USD","dateTimestamp":1788235200000,"payDate":"2026-09-15"},{"date":"2026-08-03","symbol":"IDE","amount":0.1,"announcedDate":"2026-07-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-03","defaultRemindTime":1785763800000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-03","currency":"USD","dateTimestamp":1785729600000,"payDate":"2026-08-17"},{"date":"2026-07-01","symbol":"IDE","amount":0.1,"announcedDate":"2026-06-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-01","defaultRemindTime":1782912600000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-15","payableDate":"2026-07-01","currency":"USD","dateTimestamp":1782878400000,"payDate":"2026-07-15"},{"date":"2026-06-01","symbol":"IDE","amount":0.1,"announcedDate":"2026-05-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-01","defaultRemindTime":1780320600000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-15","payableDate":"2026-06-01","currency":"USD","dateTimestamp":1780286400000,"payDate":"2026-06-15"},{"date":"2026-05-01","symbol":"IDE","amount":0.1,"announcedDate":"2026-04-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-05-01","defaultRemindTime":1777642200000,"name":"Voya Infrastructure Industrials and Materials Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-05-15","payableDate":"2026-05-01","currency":"USD","dateTimestamp":1777608000000,"payDate":"2026-05-15"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IDE\",market:\"US\",,,undefined,":[{"executeDate":"2016-10-03","recordDate":"2016-10-05","paymentDate":"2016-10-17","value":0.365,"currency":"USD"},{"executeDate":"2016-12-28","recordDate":"2016-12-30","paymentDate":"2017-01-17","value":0.29,"currency":"USD"},{"executeDate":"2017-04-03","recordDate":"2017-04-05","paymentDate":"2017-04-17","value":0.29,"currency":"USD"},{"executeDate":"2017-07-03","recordDate":"2017-07-06","paymentDate":"2017-07-17","value":0.29,"currency":"USD"},{"executeDate":"2017-10-03","recordDate":"2017-10-04","paymentDate":"2017-10-16","value":0.29,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IDE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IDE\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651496768","title":"Press Release: Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2651496768","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651496768?lang=en_us&edition=fundamental","pubTime":"2026-07-16 05:00","pubTimestamp":1784149200,"startTime":"0","endTime":"0","summary":"Voya Asia Pacific High Dividend Equity Income Fund.                                                     $0.100The following table sets forth an estimate of the sources of each Fund's July distribution and its cumulative distributions paid this fiscal year to date. Amounts are expressed on a per common share basis and as a percentage of the distribution amount.Data as of 6/30/2026. Estimated Sources                             Tax YTD                        Estimated Tax YTD Percentages. of Current Distribution                      Estimated Sources of Distribution            of Distribution. Per Share    Investment   LT     ST    Return of   Per Share    Investment   LT     ST      of     Investment   LT     ST    Return of. Distribution    Income    Gains  Gains   Capital   Distribution    Income    Gains  Gains  Capital    Income    Gains  Gains   Capital. ------------  ----------  -----  -----  ---------  ------------  ----------  -----  -----","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4184","IHD","LU1878469433.USD","REZ","BK4022","BK4585","LU0211331839.USD","EQR","LU0061475181.USD","BK4232","IGD","IAE","VOYA","IDE","NAV","BK4215","BK4588","IGA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127911630","title":"Power Grids Across Provinces Collaborate for Seamless Infrastructure Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=1127911630","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127911630?lang=en_us&edition=fundamental","pubTime":"2026-07-05 08:12","pubTimestamp":1783210322,"startTime":"0","endTime":"0","summary":"In a recent collaborative effort, more than 60 technicians from the power supply departments of Haining City in Zhejiang Province and Hanshan County in Anhui Province gathered at the Yangguang Shiji...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NFRA","HWAY","PSCU","TEMP","SPRX","FUTY","GRID","IGF","GII","NBET","HEAT","IDE","BKGI","EFRA","ACES","UPGR","HVAC","VCLN","PWER","IPAV","INFR","NVIR","RSPU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643859407","title":"Press Release: Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2643859407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643859407?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:15","pubTimestamp":1781554500,"startTime":"0","endTime":"0","summary":"Voya Investment Management, the asset management business of Voya Financial, Inc. , announced today the distributions on the common shares of five of its closed-end funds: Voya Global Advantage and Premium Opportunity Fund , Voya Global Equity Dividend and Premium Opportunity Fund , Voya Infrastructure, Industrials and Materials Fund , Voya Asia Pacific High Dividend Equity Income Fund , and Voya Emerging Markets High Dividend Equity Fund .With respect to each Fund, the distribution will be paid on July 15, 2026, to shareholders of record on July 1, 2026. The ex-dividend date is July 1, 2026. The distribution per share for each Fund is as follows:. The following table sets forth an estimate of the sources of each Fund's June distribution and its cumulative distributions paid this fiscal year to date. Amounts are expressed on a per common share basis and as a percentage of the distribution amount.Estimated Sources                             Tax YTD                        Estimated Tax ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOYA","BK4232","IDE","LU0061475181.USD","BK4588","BK4585","IGD","LU1878469433.USD","IHD","IGA","IAE","BK4022","EQR","LU0211331839.USD","NAV","BK4215","BK4184","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643785376","title":"Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND, VOYA GLOBAL EQUITY DIVIDEND AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2643785376","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643785376?lang=en_us&edition=fundamental","pubTime":"2026-06-16 04:05","pubTimestamp":1781553900,"startTime":"0","endTime":"0","summary":"Voya Global Advantage and Premium Opportunity Fund , Voya Global Equity Dividend and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund   today announced important information concerning the Funds' distributions declared in May 2026. This press release is issued as required by the Funds' Managed Distribution Plan  and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the June distribution. It is not determinative of the tax character of the Funds' distributions for the 2026 calendar year. Shareholders should note that the Funds' total regular distribution amount is subject to change as a result of market conditions or other factors.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGD","NAV","LU0061475181.USD","IGA","BK4184","IDE","FUND","LU0211331839.USD","VOYA","LU1878469433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638984556","title":"PROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2638984556","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638984556?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"SAN JOSE, Calif., May  28, 2026  (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302797/0/en/PROCEPT-BioRobotics-Advances-Prostate-Cancer-Program-with-WATER-IV-Study-Enrollment-Completion-and-Expanded-IDE-Approval.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRCT","IDE","BK4082","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638792235","title":"CGBIO Signs Global Clinical and Exclusive Commercialization Agreement for NOVOSIS in the U.S., Canada and Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2638792235","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638792235?lang=en_us&edition=fundamental","pubTime":"2026-05-27 14:00","pubTimestamp":1779861600,"startTime":"0","endTime":"0","summary":"DePuy Synthes secures exclusive commercialization rights in North America and Australia; the two companies to jointly advance global clinical development and regulatory approvals, including FDA IDE and PMA pathways. Full-scale entry into North America, the world's largest bone graft substitute market; strategic partnership to expand in orthopaedics and bone regeneration sectors. SEOUL, South Korea, May 27, 2026 /PRNewswire/ -- CGBIO, a regenerative medicine company , announced that it has entered into a global clinical development and exclusive commercialization agreement with DePuy Synthes, a global orthopaedics solutions company, for the NOVOSIS bone graft substitute product portfolio in the United States, Canada, and Australia.'Novosis Putty' Product image. Under the agreement, DePuy Synthes will secure exclusive commercialization rights for the NOVOSIS portfolio in the U.S., Canada, and Australia, while the two companies will jointly advance global clinical development and regulato","market":"hk","thumbnail":"https://mma.prnewswire.com/media/2988440/image1.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2988440/image1.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/cgbio-signs-global-clinical-and-exclusive-commercialization-agreement-for-novosis-in-the-us-canada-and-australia-302782710.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["STW.AU","IDE","BEAR.AU","IMLC.AU","SLF.AU","EIGA.AU","DACE.AU","GEAR.AU","IISV.AU","OZR.AU","BBOZ.AU","IOZ.AU","E200.AU","ZYAU.AU","XJO.AU","XKO.AU","VAS.AU","XAO.AU","GIVE.AU","OZF.AU","QRE.AU","VAP.AU","QFN.AU","IIGF.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636100612","title":"Press Release: Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2636100612","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636100612?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:01","pubTimestamp":1779134460,"startTime":"0","endTime":"0","summary":"- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile -. - Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company's first U.S. pivotal study -. - Pooled data from two pancreatic cancer trials presented at Digestive Disease Week  2026 demonstrated 100% local disease control and favorable safety, the first oral presentation of Alpha DaRT pancreatic data at a premier international gastroenterology conference -. - Abstracts accepted for presentation at the 2026 ASCO Annual Meeting and at the AHNS 12th International Conference on Head and Neck Cancer, reflecting growing scientific recognition across multiple solid tumor indications -. - FDA approval of an IDE supplement to expand the IMPACT pancreatic cancer trial to patients receiving gemcitabine with Abraxane  and recruit additional patients -. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRTS","IDE","BK4022","BK4232","R","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635037484","title":"Press Release: Voya Equity Closed End Funds Declare Distributions","url":"https://stock-news.laohu8.com/highlight/detail?id=2635037484","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635037484?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:10","pubTimestamp":1778875800,"startTime":"0","endTime":"0","summary":"Voya Investment Management, the asset management business of Voya Financial, Inc. , announced today the distributions on the common shares of five of its closed-end funds: Voya Global Advantage and Premium Opportunity Fund , Voya Global Equity Dividend and Premium Opportunity Fund , Voya Infrastructure, Industrials and Materials Fund , Voya Asia Pacific High Dividend Equity Income Fund , and Voya Emerging Markets High Dividend Equity Fund .With respect to each Fund, the distribution will be paid on June 15, 2026, to shareholders of record on June 1, 2026. The ex-dividend date is June 1, 2026. The distribution per share for each Fund is as follows:. The following table sets forth an estimate of the sources of each Fund's May distribution and its cumulative distributions paid this fiscal year to date. Amounts are expressed on a per common share basis and as a percentage of the distribution amount.Estimated Sources                             Tax YTD                        Estimated Tax Y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IAE","BK4232","BK4585","IHD","LU0061475181.USD","VOYA","BK4215","R","BK4022","BK4184","BK4588","IGA","LU0211331839.USD","NAV","LU1878469433.USD","IGD","IDE","EQR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635403761","title":"Voya funds IGA, IDE declare May monthly distributions of $0.085, $0.1 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2635403761","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635403761?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875559,"startTime":"0","endTime":"0","summary":"Voya Financial monthly cash distributions set for May 15, 2026 under managed distribution plan for closed-end funds Voya Global Advantage and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund .IGA May payout estimated to be sourced mainly from realized short-term gains; IDE estimated to be sourced mainly from realized long-term gains.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voya Financial Inc. published the original content used to generate this news brief via Business Wire  on May 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL5czkgJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGA","LU0211331839.USD","IDE","BK7028","BK4184","MTS.AU","LU0061475181.USD","LU1878469433.USD","VOYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635698037","title":"Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2635698037","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635698037?lang=en_us&edition=fundamental","pubTime":"2026-05-16 04:05","pubTimestamp":1778875500,"startTime":"0","endTime":"0","summary":"Voya Global Advantage and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund   today announced important information concerning the Funds' distributions declared in April 2026. This press release is issued as required by the Funds' Managed Distribution Plan  and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the May distribution. It is not determinative of the tax character of the Funds' distributions for the 2026 calendar year. Shareholders should note that the Funds' total regular distribution amount is subject to change as a result of market conditions or other factors.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","FUND","NAV","LU1878469433.USD","BK4184","LU0211331839.USD","IDE","IGA","VOYA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635996721","title":"Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2635996721","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635996721?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:27","pubTimestamp":1778794020,"startTime":"0","endTime":"0","summary":"Submitted Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) to initiate a U.S. clinical study for fully implantable continuous blood glucose monitoring ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3295471/0/en/Glucotrack-Reports-First-Quarter-2026-Financial-Results-and-Recent-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PAB","IDE","GCTK","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635222758","title":"Press Release: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635222758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635222758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:05","pubTimestamp":1778702700,"startTime":"0","endTime":"0","summary":"NEPHRO CRRT clinical study expected to be completed this year. Cash and investments of $21.1 million at March 31, 2026. Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET. SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. , , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial results and provided a corporate update.-- In March 2026, announced reaching the 35-patient enrollment milestone,representing 50% enrollment in the NEPHRO CRRT study. Enrollment has. continued to increase since this announcement, with study completion. leaders  focused on anticoagulants used during CRRT and the. Study of the Safety and Efficacy of Niyad in Patients Undergoing. Continuous Renal Replacement Therapy Who Cannot Tolerate Heparin or Are. at a Higher Risk of Bleeding\" and, \"In Vivo Assessment of Nafamostat, A. Novel Regio","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARDS","BK4232","TLPH","IDE","BK4007","BK4139","R","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633108657","title":"GlucoTrack Files IDE for Implantable Glucose Monitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2633108657","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633108657?lang=en_us&edition=fundamental","pubTime":"2026-05-08 05:35","pubTimestamp":1778189700,"startTime":"0","endTime":"0","summary":"GlucoTrack ( ($GCTK) ) has issued an announcement. On May 7, 2026, Glucotrack announced that it has submitted an Investigational Device Exemption a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glucotrack-files-ide-for-implantable-glucose-monitor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glucotrack-files-ide-for-implantable-glucose-monitor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632064795","title":"InspireMD announces FDA approval of IDE application for CGUARDIANS III study","url":"https://stock-news.laohu8.com/highlight/detail?id=2632064795","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632064795?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:11","pubTimestamp":1777666260,"startTime":"0","endTime":"0","summary":"InspireMD (NSPR) announced that the U.S. FDA has approved the company’s Investigational Device Exemption Application to initiate the CGUARDIANS III...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inspiremd-announces-fda-approval-of-ide-application-for-cguardians-iii-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inspiremd-announces-fda-approval-of-ide-application-for-cguardians-iii-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDE","III","NSPR","BK4134","BK4585","LABU","BK4588","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631514029","title":"enVVeno Medical Wins FDA IDE for TAVVE Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2631514029","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631514029?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:56","pubTimestamp":1777467417,"startTime":"0","endTime":"0","summary":"enVVeno Medical ( ($NVNO) ) just unveiled an update. On April 29, 2026, enVVeno Medical announced that the U.S. Food and Drug Administration grante...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/envveno-medical-wins-fda-ide-for-tavve-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/envveno-medical-wins-fda-ide-for-tavve-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IDE","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630354423","title":"Adagio Medical reports six-month results from Fulcrum-VT IDE trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2630354423","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630354423?lang=en_us&edition=fundamental","pubTime":"2026-04-27 01:30","pubTimestamp":1777224632,"startTime":"0","endTime":"0","summary":"Adagio Medical (ADGM) reported six month results from its Fulcrum-VT Investigational Device Exemption, IDE, clinical trial, which will be used to s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adagio-medical-reports-six-month-results-from-fulcrum-vt-ide-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adagio-medical-reports-six-month-results-from-fulcrum-vt-ide-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADGM","BK4082","VT","IDE","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629832984","title":"Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT® IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane® (Nab-Paclitaxel)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629832984","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629832984?lang=en_us&edition=fundamental","pubTime":"2026-04-23 21:02","pubTimestamp":1776949320,"startTime":"0","endTime":"0","summary":"- IDE supplement expands trial to the other primary standard-of-care chemotherapy for pancreatic cancer patients, alongside mFOLFIRINOX - - IDE supplement also expands total trial size from 30 to 40 p","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/23/3280027/0/en/Alpha-Tau-Announces-FDA-Approval-of-IDE-Supplement-to-Expand-Alpha-DaRT-IMPACT-Trial-to-Patients-with-Pancreatic-Cancer-Receiving-Gemcitabine-with-Abraxane-Nab-Paclitaxel.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","IDE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629035163","title":"Programmable Logic Redefined for Simpler, Smarter, Fully Integrated Designs","url":"https://stock-news.laohu8.com/highlight/detail?id=2629035163","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629035163?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:34","pubTimestamp":1776771240,"startTime":"0","endTime":"0","summary":"Microchip’s CLB-based PIC MCUs combine programmable logic and embedded control in a single device to help reduce latency, cost and design complexityCHANDLER, Ariz., April  21, 2026 (GLOBE NEWSWIRE) --","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3277811/0/en/Programmable-Logic-Redefined-for-Simpler-Smarter-Fully-Integrated-Designs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4179","CLB","IDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237759","title":"Voya funds IGA, IDE declare April monthly distributions of $0.085 and $0.10 per share","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237759","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237759?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:11","pubTimestamp":1776283885,"startTime":"0","endTime":"0","summary":"Voya Global Advantage and Premium Opportunity Fund  declared monthly distribution of $0.085 per share, payable April 15, 2026.IGA April distribution estimate: $0.031 from net investment income, $0.054 from net realized long-term capital gains.IDE April distribution estimate: $0.023 from net investment income, $0.077 from net realized long-term capital gains.Annualized current distribution rate as of March 31, 2026: 9.89% for IGA, 9.11% for IDE.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voya Financial Inc. published the original content used to generate this news brief via Business Wire  on April 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL6pXbJf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IGA","LU1878469433.USD","BK4184","VOYA","LU0211331839.USD","LU0061475181.USD","IDE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237794","title":"Press Release: VOYA GLOBAL ADVANTAGE AND PREMIUM OPPORTUNITY FUND & VOYA INFRASTRUCTURE, INDUSTRIALS AND MATERIALS FUND ANNOUNCES PAYMENT OF MONTHLY DISTRIBUTION","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237794","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237794?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:10","pubTimestamp":1776283800,"startTime":"0","endTime":"0","summary":"Voya Global Advantage and Premium Opportunity Fund  and Voya Infrastructure, Industrials and Materials Fund   today announced important information concerning the Funds' distributions declared in March 2026. This press release is issued as required by the Funds' Managed Distribution Plan  and an exemptive order received from the U.S. Securities and Exchange Commission. The Board of Trustees has approved the implementation of the Plan to make monthly cash distributions to common shareholders, stated in terms of a fixed amount per common share. This information is sent to you for informational purposes only and is an estimate of the sources of the April distribution. It is not determinative of the tax character of the Funds' distributions for the 2026 calendar year. Shareholders should note that the Funds' total regular distribution amount is subject to change as a result of market conditions or other factors.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VOYA","IDE","BK4184","LU0211331839.USD","LU1878469433.USD","NAV","FUND","LU0061475181.USD","IGA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}